Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD
Primary Purpose
Brain Injuries, Traumatic, Neurocognitive Disorders, Brain Injuries
Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Tolcapone
Sponsored by
About this trial
This is an interventional treatment trial for Brain Injuries, Traumatic
Eligibility Criteria
TBI and ABI Patients Inclusion Criteria
- Age 18-70
- Diagnosis of mild, moderate, or severe TBI, or history of ABI with classification to be made based on parameters at the time of the index event or acquired brain injury.
- Index event resulting in Traumatic or Acquired Head Injury occurred >12 months prior to trial initiation
- A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of TBI or ABI
- Proficient in the English language
- Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
- Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the referring Sheppard Pratt physician.
- Stable medication dose and regimen for 2 months
NCD Patients Inclusion Criteria
- Age 60-75
- NCD diagnosed by a Sheppard Pratt physician, per DSM-5
- No abnormalities on other serum tests to rule out other cause of cognitive impairment: TSH, B12, CBC, Chemistry screen, and RPR.
- Recent structural neuroimaging (within 1 year or since the time of the onset of cognitive complaint)-noncontrast head CT or MRI-to rule out any gross lesion inconsistent with the diagnosis of MCI (e.g. subdural hematoma, normal pressure hydrocephalus, demyelinating lesion, infarct, or mass lesion)
- Proficient in the English language
- A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of NCD
- Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
- Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the impression of the referring Sheppard Pratt physician.
- Stable medication dose and regimen for 2 months
Exclusion Criteria for All Patients:
- History of, or active, liver disease or abnormal liver function tests--if the patient currently has elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST) levels that exceed 2 times the upper limit of normal [Normal Reference Ranges ALT (Male: 4-40 IU/L, Female: 4-40 IU/L), AST (Male: 4-31 IU/L, Female: 4-37 IU/L) or the ratio of AST:ALT has exceeded 2:1
- Active alcohol use disorder, as defined by DSM-5, of any severity mild, moderate, or severe
- History of, or active, cardiovascular disease defined as: coronary heart disease, manifested by myocardial infarction, angina pectoris, or heart failure
- Uncontrolled hypo-or hypertension based on Joint National Committee criteria (JNC7) Hypotension: Systolic<90mmHg or diastolic<60mmHg Hypertension: Systolic >140mmHg or diastolic>90 mmHg)
- History of extra-pyramidal symptoms (e.g. tardive dyskinesia, neuroleptic malignant syndrome, or QT prolongation) while on a first-generation anti-psychotic
- Active illicit substance use, resulting in a substance use disorder as defined by DSM-5, of any severity mild, moderate, or severe
- Patient is currently taking tolcapone or any of the following medications that can interact with tolcapone resulting in an adverse events: another COMT inhibitor, benserazide, α-methyldopa, dobutamine, apomorphine, isoproterenol, clozapine, MAO inhibitor
- Known allergy or serious adverse reaction to tolcapone
- Participated in any investigational drug trial in the past 30 days.
- Pregnant or planning to become pregnant during the study period
- Breastfeeding or planning to breastfeed during the study period.
Other Exclusion Criteria for TBI Patients
• Presence of pre-morbid/pre-TBI cognitive impairment or behavioral dysfunction, as per informant or medical documentation
Sites / Locations
- Sheppard Pratt Health System
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Open-Label
Arm Description
Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
Outcomes
Primary Outcome Measures
Change from Baseline Clinical Global Impression Scale (CGI) to two weeks after medication administration
Secondary Outcome Measures
Change from Baseline TBI-QoL to two weeks after medication administration
Questions from the TBI-QoL battery, which consists of tests to assess items on domains of emotion, social activity, physical activity, and cognition
Change from Baseline NIH Toolbox Cognition Battery to two weeks after medication administration
A cognition battery developed by NIH, which consists of tests to assess Executive Function, Attention, Episodic Memory, Language, Processing Speed and Working Memory.
Full Information
NCT ID
NCT02652598
First Posted
January 6, 2016
Last Updated
January 17, 2017
Sponsor
Sheppard Pratt Health System
Collaborators
Lieber Institute for Brain Development (LIBD)
1. Study Identification
Unique Protocol Identification Number
NCT02652598
Brief Title
Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD
Official Title
A Proof of Concept Open-label Study to Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With Traumatic Brain Injury (TBI), Other Acquired Brain Injuries (ABI), or a Diagnosis of Neurocognitive Disorder (NCD)
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 2015 (undefined)
Primary Completion Date
January 2020 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sheppard Pratt Health System
Collaborators
Lieber Institute for Brain Development (LIBD)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The experimental design is an open-label two-week trial of tolcapone to evaluate which clinical domains are affected by tolcapone treatment and to identify "responders" to tolcapone treatment in the two subject groups (BI and NCD)
Detailed Description
Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
Clinical Instruments for patients:
Question banks from large patient-reported outcome measure initiatives will be used and administered and used by computerized-adaptive tests (CATs). These include the TBI-QoL for patients with TBI and question banks from the patient-reported outcome measure information systems (PROMIS) and neurology quality of life measurement initiative (Neuro-QoL). Patients will answer questions related to their mobility, fatigue, pain interference, positive affect and well-being, depression, anxiety, anger and irritability, and emotional and behavioral dyscontrol.
Clinical Global Impressions Scale
Geriatric Depression Scale-15
State-Trait Anxiety Inventory
Hopkins Adult Reading Test
Frontal Systems Behavior Scale
Montreal Cognitive Assessment
Trails A&B
Modified Wisconsin Card Sorting Test
NIH Toolbox
Perceptual Comparison Test
Brief Test of Attention
Hopkins Verbal Learning Test
Brief Visuospatial Memory Test
Calibrated Ideational Fluency Assessment
Profile of Mood States
Digit Span
Clinical Instruments for Informants:
Neuropsychiatry Inventory
Apathy evaluation scale
Overt aggression scale
Frontal Systems Behavior Scale
Laboratory Measures:
Blood sample for genotyping
Blood sample for assessing COMT activity.
Blood sample for a laboratory profile including CBC, CMP, TSH, Hepatitis Panel (B and C), and RPR
A urine analysis, urine drug screen, and a urine pregnancy test
In addition for NCD patients: a blood sample for tests including Serum Calcium, B12, ESR, and C-reactive protein
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Injuries, Traumatic, Neurocognitive Disorders, Brain Injuries
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Open-Label
Arm Type
Experimental
Arm Description
Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
Intervention Type
Drug
Intervention Name(s)
Tolcapone
Other Intervention Name(s)
Tasmar
Primary Outcome Measure Information:
Title
Change from Baseline Clinical Global Impression Scale (CGI) to two weeks after medication administration
Time Frame
Up to 2 weeks
Secondary Outcome Measure Information:
Title
Change from Baseline TBI-QoL to two weeks after medication administration
Description
Questions from the TBI-QoL battery, which consists of tests to assess items on domains of emotion, social activity, physical activity, and cognition
Time Frame
Up to 2 weeks
Title
Change from Baseline NIH Toolbox Cognition Battery to two weeks after medication administration
Description
A cognition battery developed by NIH, which consists of tests to assess Executive Function, Attention, Episodic Memory, Language, Processing Speed and Working Memory.
Time Frame
Up to 2 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
TBI and ABI Patients Inclusion Criteria
Age 18-70
Diagnosis of mild, moderate, or severe TBI, or history of ABI with classification to be made based on parameters at the time of the index event or acquired brain injury.
Index event resulting in Traumatic or Acquired Head Injury occurred >12 months prior to trial initiation
A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of TBI or ABI
Proficient in the English language
Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the referring Sheppard Pratt physician.
Stable medication dose and regimen for 2 months
NCD Patients Inclusion Criteria
Age 60-75
NCD diagnosed by a Sheppard Pratt physician, per DSM-5
No abnormalities on other serum tests to rule out other cause of cognitive impairment: TSH, B12, CBC, Chemistry screen, and RPR.
Recent structural neuroimaging (within 1 year or since the time of the onset of cognitive complaint)-noncontrast head CT or MRI-to rule out any gross lesion inconsistent with the diagnosis of MCI (e.g. subdural hematoma, normal pressure hydrocephalus, demyelinating lesion, infarct, or mass lesion)
Proficient in the English language
A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of NCD
Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the impression of the referring Sheppard Pratt physician.
Stable medication dose and regimen for 2 months
Exclusion Criteria for All Patients:
History of, or active, liver disease or abnormal liver function tests--if the patient currently has elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST) levels that exceed 2 times the upper limit of normal [Normal Reference Ranges ALT (Male: 4-40 IU/L, Female: 4-40 IU/L), AST (Male: 4-31 IU/L, Female: 4-37 IU/L) or the ratio of AST:ALT has exceeded 2:1
Active alcohol use disorder, as defined by DSM-5, of any severity mild, moderate, or severe
History of, or active, cardiovascular disease defined as: coronary heart disease, manifested by myocardial infarction, angina pectoris, or heart failure
Uncontrolled hypo-or hypertension based on Joint National Committee criteria (JNC7) Hypotension: Systolic<90mmHg or diastolic<60mmHg Hypertension: Systolic >140mmHg or diastolic>90 mmHg)
History of extra-pyramidal symptoms (e.g. tardive dyskinesia, neuroleptic malignant syndrome, or QT prolongation) while on a first-generation anti-psychotic
Active illicit substance use, resulting in a substance use disorder as defined by DSM-5, of any severity mild, moderate, or severe
Patient is currently taking tolcapone or any of the following medications that can interact with tolcapone resulting in an adverse events: another COMT inhibitor, benserazide, α-methyldopa, dobutamine, apomorphine, isoproterenol, clozapine, MAO inhibitor
Known allergy or serious adverse reaction to tolcapone
Participated in any investigational drug trial in the past 30 days.
Pregnant or planning to become pregnant during the study period
Breastfeeding or planning to breastfeed during the study period.
Other Exclusion Criteria for TBI Patients
• Presence of pre-morbid/pre-TBI cognitive impairment or behavioral dysfunction, as per informant or medical documentation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert J Schloesser, MD
Organizational Affiliation
Sheppard Pratt Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sheppard Pratt Health System
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21204
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD
We'll reach out to this number within 24 hrs